HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MICOT PHARMA-B

29.000

+0.3401.19%

Volume:205.80K

Turnover:5.94M

Market Cap:9.62B

PE:- -

High:29.060

Open:28.640

Low:28.600

Close:28.660

52wk High:45.040

52wk Low:27.000

Shares:331.74M

HK Float Shares:280.07M

Volume Ratio:1.15

T/O Rate:0.07%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:-33.17%

PB:-8.48

PE(LYR):- -

PS:28150.74

Loading ...

Overview Company News Filings

MICOT Pharma's Stroke Drug Completes Mid-Stage Trial in China

Shaanxi Micot Says Phase II Trial of Mt200605 Meets Primary Endpoint in Acute Ischemic Stroke in China

MICOT PHARMA-B (02335) Selected for Hang Seng Composite Index Inclusion

Shaanxi Micot Pharmaceutical Joins Hang Seng Composite Index from Sept. 7

Shaanxi Micot Pharmaceutical Technology Co - to be Included in Hang Seng Composite Index Effective 7 September 2026

THOMSON REUTERS

Hong Kong Stock Market Flash | Micot Pharma-B (02335) Surges Nearly 6% in Afternoon Session as Innovative Drug XTL6001 Makes Third Appearance on International Academic Stage

Shaanxi Micot Pharma to Present Results of XTL6001 at International Conferences

MT Newswires Live

Shaanxi Micot Says Xtl6001 Study Accepted for Oral Presentation at EASD 2026

Micot Pharma Sets 28 August 2026 Board Meeting to Review H1 2026 Results and Potential Interim Dividend

Bulletin Express

Shaanxi Micot Pharma Schedules Board Meeting to Review Interim Results

MICOT PHARMA-B (02335) Surges 3% After MT200605 Data Accepted for Oral Presentation at 2026 World Stroke Conference

Micot Pharma’s MT200605 Data Selected for Oral Presentation at 2026 World Stroke Congress, Phase II Hits Primary Endpoint

Bulletin Express

Shaanxi Micot Says Mt200605 Phase I, Preclinical Data Accepted for Oral Presentation at World Stroke Congress 2026

Micot Pharma Reports Stable Share Base for July 2026, Confirms Public Float Compliance

Bulletin Express

Hong Kong Stock Movers: MICOT PHARMA-B Surges Over 3% After Phase II Trial for Acute Ischemic Stroke Meets Primary Endpoint

Micot Pharma Gets Topline Results from AIS Drug Candidate Study; Shares Jump 3%

MT Newswires Live

Shaanxi Micot Pharmaceutical Technology Co Says Phase II Trial of Mt200605 for AIS Reaches Primary Endpoint

Shaanxi Micot Pharmaceutical Technology Co - Phase Ii Trial of Mt200605 for Ais Reaches Primary Endpoint with Statistically Significant Outcomes

THOMSON REUTERS

MICOT PHARMA-B (02335) Completes Data Lock for Phase II Clinical Trial of MT200605 in Acute Ischemic Stroke (AIS)

Shaanxi Micot Says Phase II Trial Database Lock Completed for Stroke Drug Candidate Mt200605

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigermarketb.com/stock/02335/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02335","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02335\",,,,,undefined,":{"symbol":"02335","market":"HK","secType":"STK","nameCN":"MICOT PHARMA-B","latestPrice":29,"timestamp":1787808670101,"preClose":28.66,"halted":0,"volume":205800,"delay":0,"changeRate":0.01186322400558269,"floatShares":280071100,"shares":331740350,"eps":0,"marketStatus":"Trading","change":0.34,"latestTime":"08-27 13:31:55","open":28.64,"high":29.06,"low":28.6,"amount":5939848,"amplitude":0.01605,"askPrice":29,"askSize":200,"bidPrice":28.98,"bidSize":600,"shortable":0,"etf":0,"ttmEps":-0.609,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787818200000},"marketStatusCode":2,"adr":0,"listingDate":1782230400000,"exchange":"SEHK","adjPreClose":28.66,"openAndCloseTimeList":[[1787794200000,1787803200000],[1787806800000,1787817600000]],"volumeRatio":1.145346,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02335\",,,,,undefined,":{"symbol":"02335","floatShares":280071100,"roa":"-33.17%","roe":"--","lyrEps":0,"volumeRatio":1.145346,"shares":331740350,"dividePrice":0,"high":29.06,"amplitude":0.01605,"preClose":28.66,"low":28.6,"week52Low":27,"pbRate":"-8.48","psRate":"28150.74","week52High":45.04,"institutionHeld":0,"latestPrice":29,"committee":0.5,"eps":0,"divideRate":0,"volume":205800,"delay":0,"ttmEps":-0.609,"open":28.64,"prevYearClose":18.2,"prevWeekClose":29.36,"prevMonthClose":28.72,"prevQuarterClose":36.54,"fiveDayClose":30.2,"twentyDayClose":28.2,"sixtyDayClose":18.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02335\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"02335","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787880600000,"name":null,"time":"","dateTimestamp":1787846400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02335\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02335\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02335\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02335","date":"2026-08-25","current":-47.060755,"percent":0.883721,"low":-69.768231,"twenty":-62.654599,"median":-51.494429,"eighty":-45.605963,"high":-30.846573,"avg":-53.261505,"sd":8.911721,"marketCap":9428060747},"quantilePoints":[{"date":"2026-06-26","current":-62.263046,"twenty":-62.206329,"median":-60.152258,"eighty":-47.220229,"marketCap":13110378632},{"date":"2026-07-03","current":-59.036408,"twenty":-61.58898,"median":-58.586203,"eighty":-56.979685,"marketCap":12440263125},{"date":"2026-07-10","current":-67.90436,"twenty":-64.475349,"median":-60.719674,"eighty":-57.773147,"marketCap":14291374278},{"date":"2026-07-17","current":-63.579874,"twenty":-66.545041,"median":-62.752488,"eighty":-58.496163,"marketCap":13428849368},{"date":"2026-07-24","current":-53.390071,"twenty":-65.175311,"median":-60.719674,"eighty":-54.684103,"marketCap":11279171900},{"date":"2026-07-31","current":-45.013396,"twenty":-64.653423,"median":-59.036408,"eighty":-53.47914,"marketCap":9527582852},{"date":"2026-08-07","current":-44.926163,"twenty":-63.868877,"median":-57.071612,"eighty":-46.373695,"marketCap":9527582852},{"date":"2026-08-14","current":-46.337925,"twenty":-63.512285,"median":-53.986784,"eighty":-46.072055,"marketCap":9839418781},{"date":"2026-08-21","current":-45.768087,"twenty":-63.046152,"median":-53.612744,"eighty":-46.072055,"marketCap":9739896676},{"date":"2026-08-25","current":-44.29541,"twenty":-62.654599,"median":-51.494429,"eighty":-45.605963,"marketCap":9428060747}],"updateTime":1787766466265},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02335\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1114989011","title":"MICOT Pharma's Stroke Drug Completes Mid-Stage Trial in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1114989011","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114989011?lang=en_us&edition=fundamental","pubTime":"2026-08-26 22:42","pubTimestamp":1787755330,"startTime":"0","endTime":"0","summary":"MICOT PHARMA-B (02335) has announced the completion of a Phase II clinical trial for its self-developed candidate drug MT200605, designed to treat acute ischemic stroke (AIS).The trial demonstrated...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIS","IBBJ","BMED","PSYK","02335","BK1161","MDTX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662710265","title":"Shaanxi Micot Says Phase II Trial of Mt200605 Meets Primary Endpoint in Acute Ischemic Stroke in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2662710265","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662710265?lang=en_us&edition=fundamental","pubTime":"2026-08-26 22:39","pubTimestamp":1787755163,"startTime":"0","endTime":"0","summary":"Shaanxi Micot says Phase II trial of MT200605 meets primary endpoint in acute ischemic stroke in ChinaShaanxi Micot Pharmaceutical Technology reported completion of a Phase II China trial of MT200605 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL73JHbJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122580555","title":"MICOT PHARMA-B (02335) Selected for Hang Seng Composite Index Inclusion","url":"https://stock-news.laohu8.com/highlight/detail?id=1122580555","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122580555?lang=en_us&edition=fundamental","pubTime":"2026-08-24 12:14","pubTimestamp":1787544854,"startTime":"0","endTime":"0","summary":"MICOT PHARMA-B (02335) has announced its selection for inclusion as a constituent stock of the Hang Seng Composite Index, following the quarterly index review results released by Hang Seng Indexes...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSCI","BK1161","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661240119","title":"Shaanxi Micot Pharmaceutical Joins Hang Seng Composite Index from Sept. 7","url":"https://stock-news.laohu8.com/highlight/detail?id=2661240119","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661240119?lang=en_us&edition=fundamental","pubTime":"2026-08-24 12:05","pubTimestamp":1787544333,"startTime":"0","endTime":"0","summary":"Shaanxi Micot Pharmaceutical joins Hang Seng Composite Index from Sept. 7Shaanxi Micot Pharmaceutical Technology will be added to the Hang Seng Composite Index effective Sept. 7, 2026.Selection follow","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL1CffWY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661240186","title":"Shaanxi Micot Pharmaceutical Technology Co - to be Included in Hang Seng Composite Index Effective 7 September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2661240186","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661240186?lang=en_us&edition=fundamental","pubTime":"2026-08-24 12:04","pubTimestamp":1787544284,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44J09M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176624055","title":"Hong Kong Stock Market Flash | Micot Pharma-B (02335) Surges Nearly 6% in Afternoon Session as Innovative Drug XTL6001 Makes Third Appearance on International Academic Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1176624055","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176624055?lang=en_us&edition=fundamental","pubTime":"2026-08-18 13:50","pubTimestamp":1787032215,"startTime":"0","endTime":"0","summary":"MICOT PHARMA-B (02335) jumped nearly 6% in the afternoon session, trading up 5.94% at HK$32.12 with turnover reaching HK$12.68 million at the time of writing.On the news front, the company's...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNGR","BK1574","159992","BK1161","BK4585","IBBQ","MEDX","BK4588","02335","KCAI","VXUS","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660482480","title":"Shaanxi Micot Pharma to Present Results of XTL6001 at International Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2660482480","media":"MT Newswires Live","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660482480?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:56","pubTimestamp":1786967799,"startTime":"0","endTime":"0","summary":"Shaanxi Micot Pharmaceutical Technology's (HKG:2335) research results for XTL6001 have been accepted for presentation at multiple academic conferences in the fields of diabetes, metabolic diseases, an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ASN.AU","BK7504","BK1161","BK7095","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660548117","title":"Shaanxi Micot Says Xtl6001 Study Accepted for Oral Presentation at EASD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2660548117","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660548117?lang=en_us&edition=fundamental","pubTime":"2026-08-17 18:37","pubTimestamp":1786963036,"startTime":"0","endTime":"0","summary":"Shaanxi Micot says XTL6001 study accepted for oral presentation at EASD 2026Shaanxi Micot Pharmaceutical Technology reported XTL6001 research accepted for EASD 2026 oral sessions, signaling rising ext","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL2bqbLW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191660124","title":"Micot Pharma Sets 28 August 2026 Board Meeting to Review H1 2026 Results and Potential Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1191660124","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191660124?lang=en_us&edition=fundamental","pubTime":"2026-08-14 22:06","pubTimestamp":1786716393,"startTime":"0","endTime":"0","summary":"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (Micot Pharma) announced that its board of directors will convene on 28 August 2026 in Xi’an, Shaanxi, to review the unaudited interim results for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659142638","title":"Shaanxi Micot Pharma Schedules Board Meeting to Review Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659142638","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659142638?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:44","pubTimestamp":1786715089,"startTime":"0","endTime":"0","summary":"Shaanxi Micot Pharma schedules board meeting to review interim resultsShaanxi Micot Pharmaceutical Technology will hold a board meeting on Aug. 28, 2026.Agenda includes unaudited interim results for t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL8Bvl46:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169699749","title":"MICOT PHARMA-B (02335) Surges 3% After MT200605 Data Accepted for Oral Presentation at 2026 World Stroke Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=1169699749","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169699749?lang=en_us&edition=fundamental","pubTime":"2026-08-11 11:46","pubTimestamp":1786419979,"startTime":"0","endTime":"0","summary":"MICOT PHARMA-B (02335) rose more than 3%, trading at HK$29.94 as of the time of reporting, up 3.17%, with a turnover of HK$6.303 million. On August 10, the company announced that preclinical and...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0757428866.USD","BK4588","BK1161","LU1815336091.USD","02335","BK4585","VXUS","BK4129","KCAI","WSC","LU1878469433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103721845","title":"Micot Pharma’s MT200605 Data Selected for Oral Presentation at 2026 World Stroke Congress, Phase II Hits Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1103721845","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103721845?lang=en_us&edition=fundamental","pubTime":"2026-08-10 23:46","pubTimestamp":1786376780,"startTime":"0","endTime":"0","summary":"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (Micot Pharma) reported that pre-clinical and Phase I clinical results for its injectable neuroprotective candidate MT200605 have been accepted for...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658493738","title":"Shaanxi Micot Says Mt200605 Phase I, Preclinical Data Accepted for Oral Presentation at World Stroke Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2658493738","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658493738?lang=en_us&edition=fundamental","pubTime":"2026-08-10 22:49","pubTimestamp":1786373366,"startTime":"0","endTime":"0","summary":"Shaanxi Micot says MT200605 Phase I, preclinical data accepted for oral presentation at World Stroke Congress 2026Shaanxi Micot Pharmaceutical Technology reported MT200605 preclinical and Phase I data","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL9Fb8Sf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164063868","title":"Micot Pharma Reports Stable Share Base for July 2026, Confirms Public Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1164063868","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164063868?lang=en_us&edition=fundamental","pubTime":"2026-08-04 17:10","pubTimestamp":1785834631,"startTime":"0","endTime":"0","summary":"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (Micot Pharma) filed its monthly return for the period ended 31 July 2026, indicating no changes to either its registered or issued share capital...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102821392","title":"Hong Kong Stock Movers: MICOT PHARMA-B Surges Over 3% After Phase II Trial for Acute Ischemic Stroke Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1102821392","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102821392?lang=en_us&edition=fundamental","pubTime":"2026-08-04 14:44","pubTimestamp":1785825858,"startTime":"0","endTime":"0","summary":"MICOT PHARMA-B (02335) shares rose more than 3% in Hong Kong trading, climbing 3.4% to HK$30.40 as of the time of writing, with turnover reaching HK$20.4952 million.The company announced on August 3...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSYK","VXUS","MDTX","IBBQ","BK1161","BK4585","IBBJ","KCAI","BK4588","BMED","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656587054","title":"Micot Pharma Gets Topline Results from AIS Drug Candidate Study; Shares Jump 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656587054","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656587054?lang=en_us&edition=fundamental","pubTime":"2026-08-04 14:27","pubTimestamp":1785824827,"startTime":"0","endTime":"0","summary":"Shaanxi Micot Pharmaceutical Technology's  phase II clinical trial of MT200605 for the treatment of AIS obtained top-line results, according to a Monday Hong Kong bourse filing.Shares of the company were nearly 3% in Tuesday afternoon trading.Results showed that the study reached its primary endpoint with statistically significant and clinically meaningful outcomes, with the drug showing a favorable efficacy trend and safety and tolerability profile.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656370053","title":"Shaanxi Micot Pharmaceutical Technology Co Says Phase II Trial of Mt200605 for AIS Reaches Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2656370053","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656370053?lang=en_us&edition=fundamental","pubTime":"2026-08-03 23:33","pubTimestamp":1785771237,"startTime":"0","endTime":"0","summary":"BRIEF-Shaanxi Micot Pharmaceutical Technology Co Says Phase II Trial Of MT200605 For AIS Reaches Primary EndpointAug 3 -Shaanxi Micot Pharmaceutical Technology Co Ltd2335.HK:PHASE II TRIAL OF MT200605 FOR AIS REACHES PRIMARY ENDPOINT WITH STATISTICALLY SIGNIFICANT OUTCOMESFurther company coverage:2335.HK","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nFWN44011U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656370837","title":"Shaanxi Micot Pharmaceutical Technology Co - Phase Ii Trial of Mt200605 for Ais Reaches Primary Endpoint with Statistically Significant Outcomes","url":"https://stock-news.laohu8.com/highlight/detail?id=2656370837","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656370837?lang=en_us&edition=fundamental","pubTime":"2026-08-03 22:53","pubTimestamp":1785768838,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nFWN44011U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142184840","title":"MICOT PHARMA-B (02335) Completes Data Lock for Phase II Clinical Trial of MT200605 in Acute Ischemic Stroke (AIS)","url":"https://stock-news.laohu8.com/highlight/detail?id=1142184840","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142184840?lang=en_us&edition=fundamental","pubTime":"2026-07-24 19:48","pubTimestamp":1784893701,"startTime":"0","endTime":"0","summary":"MICOT PHARMA-B (02335) has announced that the Phase II clinical trial for its candidate drug MT200605, designed to treat acute ischemic stroke, has successfully completed database locking.MT200605 is...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBJ","MDTX","BMED","AIS","02335","PSYK","IBBQ","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653814680","title":"Shaanxi Micot Says Phase II Trial Database Lock Completed for Stroke Drug Candidate Mt200605","url":"https://stock-news.laohu8.com/highlight/detail?id=2653814680","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653814680?lang=en_us&edition=fundamental","pubTime":"2026-07-24 19:41","pubTimestamp":1784893290,"startTime":"0","endTime":"0","summary":"Shaanxi Micot says Phase II trial database lock completed for stroke drug candidate MT200605Shaanxi Micot Pharmaceutical Technology reported a database lock for its Phase II China trial of MT200605 in","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDL57gwb9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":51,"code":"91000000","status":"200"}]}}